Research data supporting ''Modulating Drug Release from Short Poly(ethylene glycol) Block Initiated Poly(L-lactide) Di-Block Copolymers''
Citation
Azhari, Z., Smith, P., McMahon, S., Wang, W., & Cameron, R. (2022). Research data supporting ''Modulating Drug Release from Short Poly(ethylene glycol) Block Initiated Poly(L-lactide) Di-Block Copolymers'' [Dataset]. https://doi.org/10.17863/CAM.82584
Description
This Dataset relates to the paper investigating drug release from a novel series of mPEG-functionalised PLLA polymers whose individual components (PEG and PLLA) have regulatory FDA approval. Two processing methods were explored to understand their effect on the morphology and drug release profiles of the polymers, with and without mPEG functionalisation. In the first method the polymer and Propranolol.HCl drug powders were mixed together before injection moulding. In the second method, supercritical CO2 was used to mix the polymer and drug before injection moulding. When non- functionalised PLLA was processed through injection moulding alone, there were no signs of polymer-drug interaction, and the drug was confined to crystals on the surface. This resulted in up to 85 wt% burst release of propranolol.HCl after one day of incubation. By contrast, injection moulding of mPEG-functionalised polymers resulted in the partial dissolution of drug in the polymer matrix and a smaller burst (50 wt% drug) followed by sustained release. This initial burst release was completely eliminated from the profile of mPEG-functionalised polymers processed via supercritical CO2. The addition of mPEG facilitated the distribution of the drug into the bulk matrix of the polymer. Paired with supercritical CO2 processing, the drug release profile showed a slow, sustained release throughout the 4 months of the study.
Format
MS Excel
Keywords
Drug Release, Processing, Hydrolysis, Bioresorbable, Biomaterials
Relationships
Sponsorship
This research was supported by the Engineering and Physical Sciences Research Council (EPSRC)
under grant agreement No. EP/L504920/1 and has received funding from the European Union Seventh
Framework Programme (FP7/2007-2013) under grant agreement n◦
604251-ReBioStent.
Identifiers
This record's DOI: https://doi.org/10.17863/CAM.82584
Rights
Attribution 4.0 International (CC BY 4.0)
Licence URL: https://creativecommons.org/licenses/by/4.0/
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.